Cholangiocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034
The 7 major Cholangiocarcinoma markets reached a value of US$ 952.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2,590.7 Million by 2034, exhibiting a growth rate (CAGR) of 9.5% during 2024-2034.
Cholangiocarcinoma market is currently driven by factors such as a rising geriatric population, increasing number of patients with liver disease, a large smoking population, growing number of patients with diabetes, and rising safety and efficacy of current and emerging therapies, etc. Furthermore, the introduction of technologically advanced diagnostics that assist in monitoring tumour progression, assessing therapeutic response and clinical prognosis, and detecting recurrent tumours is further creating a positive outlook for the market.
Cholangiocarcinoma is a type of cancer involving the mutation of epithelial cells in the bile ducts. Some of the common factors responsible for the disease development include prolonged inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection caused due to liver flukes parasite, and exposure to harmful chemicals and toxins. It occurs mostly in people over 65 years, though it may occur at any age. Cholangiocarcinoma is also slightly more common in men compared to women. The indication usually does not cause symptoms till it reaches an advanced stage and has spread to other organs and tissues. Few patients may, however, experience early symptoms. These may involve the yellowing of the skin and the whites of the eyes, itchiness of skin, light-colored stool, pain/bloating in the stomach, nausea and vomiting, loss of appetite/unexplained weight loss, fever, and fatigue.
IMARC Group’s new report 'Cholangiocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast' provides an exhaustive analysis of the Cholangiocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Cholangiocarcinoma market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Cholangiocarcinoma across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Cholangiocarcinoma and also represents the largest market for Cholangiocarcinoma treatment. Furthermore, the current Cholangiocarcinoma treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cholangiocarcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Cholangiocarcinoma Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Cholangiocarcinoma Market
Sales of Various Drugs Across the Cholangiocarcinoma Market
Reimbursement Scenario in the Cholangiocarcinoma Market
Competitive Landscape:
This report also provides a detailed analysis of the current Cholangiocarcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Cholangiocarcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Cholangiocarcinoma market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Cholangiocarcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Cholangiocarcinoma market?
Epidemiology Insights
What is the size of the Cholangiocarcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Cholangiocarcinoma across the seven major markets?
What are the key factors driving the epidemiological trend of Cholangiocarcinoma?
What will be the growth rate of Cholangiocarcinoma patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Cholangiocarcinoma drugs and what are their market performance?
What are the key pipeline Cholangiocarcinoma drugs and how are they expected to perform in the coming years?
How safe are the current marketed Cholangiocarcinoma drugs and what are their efficacies?
How safe are the late-stage pipeline Cholangiocarcinoma drugs and what are their efficacies?
What are the current treatment guidelines for Cholangiocarcinoma drugs across the seven major markets?
Who are the key companies in the Cholangiocarcinoma market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Cholangiocarcinoma market?
Cholangiocarcinoma market is currently driven by factors such as a rising geriatric population, increasing number of patients with liver disease, a large smoking population, growing number of patients with diabetes, and rising safety and efficacy of current and emerging therapies, etc. Furthermore, the introduction of technologically advanced diagnostics that assist in monitoring tumour progression, assessing therapeutic response and clinical prognosis, and detecting recurrent tumours is further creating a positive outlook for the market.
Cholangiocarcinoma is a type of cancer involving the mutation of epithelial cells in the bile ducts. Some of the common factors responsible for the disease development include prolonged inflammation in the liver, biliary stones, abnormalities in the bile duct such as cysts, infection caused due to liver flukes parasite, and exposure to harmful chemicals and toxins. It occurs mostly in people over 65 years, though it may occur at any age. Cholangiocarcinoma is also slightly more common in men compared to women. The indication usually does not cause symptoms till it reaches an advanced stage and has spread to other organs and tissues. Few patients may, however, experience early symptoms. These may involve the yellowing of the skin and the whites of the eyes, itchiness of skin, light-colored stool, pain/bloating in the stomach, nausea and vomiting, loss of appetite/unexplained weight loss, fever, and fatigue.
IMARC Group’s new report 'Cholangiocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast' provides an exhaustive analysis of the Cholangiocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Cholangiocarcinoma market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Cholangiocarcinoma across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Cholangiocarcinoma and also represents the largest market for Cholangiocarcinoma treatment. Furthermore, the current Cholangiocarcinoma treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cholangiocarcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, Current and Future Epidemiology Scenario
Historical, Current and Future Performance of the Cholangiocarcinoma Market
Historical, Current and Future Performance of Various Therapeutic Categories in the Cholangiocarcinoma Market
Sales of Various Drugs Across the Cholangiocarcinoma Market
Reimbursement Scenario in the Cholangiocarcinoma Market
Competitive Landscape:
This report also provides a detailed analysis of the current Cholangiocarcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Cholangiocarcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
What was the country-wise size of the Cholangiocarcinoma market across the seven major markets in 2023 and how will it look like in 2034?
What is the growth rate of the Cholangiocarcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the Cholangiocarcinoma market?
Epidemiology Insights
What is the size of the Cholangiocarcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) of Cholangiocarcinoma across the seven major markets?
What are the key factors driving the epidemiological trend of Cholangiocarcinoma?
What will be the growth rate of Cholangiocarcinoma patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed Cholangiocarcinoma drugs and what are their market performance?
What are the key pipeline Cholangiocarcinoma drugs and how are they expected to perform in the coming years?
How safe are the current marketed Cholangiocarcinoma drugs and what are their efficacies?
How safe are the late-stage pipeline Cholangiocarcinoma drugs and what are their efficacies?
What are the current treatment guidelines for Cholangiocarcinoma drugs across the seven major markets?
Who are the key companies in the Cholangiocarcinoma market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Cholangiocarcinoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHOLANGIOCARCINOMA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 CHOLANGIOCARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHOLANGIOCARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 CHOLANGIOCARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Cholangiocarcinoma Guidelines, Management and Treatment
8.2 Cholangiocarcinoma Treatment Algorithm
9 CHOLANGIOCARCINOMA - UNMET NEEDS
10 CHOLANGIOCARCINOMA - KEY ENDPOINTS OF TREATMENT
11 CHOLANGIOCARCINOMA - MARKETED PRODUCTS
11.1 List of Cholangiocarcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHOLANGIOCARCINOMA - PIPELINE DRUGS
12.1 List of Cholangiocarcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CHOLANGIOCARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CHOLANGIOCARCINOMA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Cholangiocarcinoma - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Cholangiocarcinoma - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Cholangiocarcinoma - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Cholangiocarcinoma - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Cholangiocarcinoma - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Cholangiocarcinoma - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Cholangiocarcinoma - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Cholangiocarcinoma - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Cholangiocarcinoma - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Cholangiocarcinoma - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Cholangiocarcinoma - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Cholangiocarcinoma - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Cholangiocarcinoma - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Cholangiocarcinoma - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Cholangiocarcinoma - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Cholangiocarcinoma - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Cholangiocarcinoma - Access and Reimbursement Overview
15 CHOLANGIOCARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 CHOLANGIOCARCINOMA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHOLANGIOCARCINOMA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 CHOLANGIOCARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHOLANGIOCARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 CHOLANGIOCARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Cholangiocarcinoma Guidelines, Management and Treatment
8.2 Cholangiocarcinoma Treatment Algorithm
9 CHOLANGIOCARCINOMA - UNMET NEEDS
10 CHOLANGIOCARCINOMA - KEY ENDPOINTS OF TREATMENT
11 CHOLANGIOCARCINOMA - MARKETED PRODUCTS
11.1 List of Cholangiocarcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHOLANGIOCARCINOMA - PIPELINE DRUGS
12.1 List of Cholangiocarcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. CHOLANGIOCARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CHOLANGIOCARCINOMA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Cholangiocarcinoma - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Cholangiocarcinoma - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Cholangiocarcinoma - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Cholangiocarcinoma - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Cholangiocarcinoma - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Cholangiocarcinoma - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Cholangiocarcinoma - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Cholangiocarcinoma - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Cholangiocarcinoma - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Cholangiocarcinoma - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Cholangiocarcinoma - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Cholangiocarcinoma - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Cholangiocarcinoma - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Cholangiocarcinoma - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Cholangiocarcinoma - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Cholangiocarcinoma - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Cholangiocarcinoma - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Cholangiocarcinoma - Access and Reimbursement Overview
15 CHOLANGIOCARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 CHOLANGIOCARCINOMA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
